

RECEIVED

MAY 16 2002

SEQUENCE LISTING

TECH CENTER 1600/2900

#14B  
Cmcy  
5/28/02

<110> Wesche, Holger  
Li, Shyun  
Tularik Inc.

<120> IRAK-4: Compositions and Methods of Use

<130> 018781-003910US

<140> US 09/759,595

<141> 2001-01-11

<150> US 60/176,395

<151> 2000-01-13

<160> 7

<170> PatentIn Ver. 2.1

<210> 1

<211> 460

<212> PRT

<213> Homo sapiens

<400> 1

Met Asn Lys Pro Ile Thr Pro Ser Thr Tyr Val Arg Cys Leu Asn Val  
1 5 10 15

Gly Leu Ile Arg Lys Leu Ser Asp Phe Ile Asp Pro Gln Glu Gly Trp  
20 25 30

Lys Lys Leu Ala Val Ala Ile Lys Lys Pro Ser Gly Asp Asp Arg Tyr  
35 40 45

Asn Gln Phe His Ile Arg Arg Phe Glu Ala Leu Leu Gln Thr Gly Lys  
50 55 60

Ser Pro Thr Ser Glu Leu Leu Phe Asp Trp Gly Thr Thr Asn Cys Thr  
65 70 75 80

Ala Gly Asp Leu Val Asp Leu Leu Ile Gln Asn Glu Phe Phe Ala Pro  
85 90 95

Ala Ser Leu Leu Leu Pro Asp Ala Val Pro Lys Thr Ala Asn Thr Leu  
100 105 110

Pro Ser Lys Glu Ala Ile Thr Val Gln Gln Lys Gln Met Pro Phe Cys  
115 120 125

Asp Lys Asp Arg Thr Leu Met Thr Pro Val Gln Asn Leu Glu Gln Ser  
130 135 140

Tyr Met Pro Pro Asp Ser Ser Ser Pro Glu Asn Lys Ser Leu Glu Val  
145 150 155 160

Ser Asp Thr Arg Phe His Ser Phe Ser Phe Tyr Glu Leu Lys Asn Val  
165 170 175

Thr Asn Asn Phe Asp Glu Arg Pro Ile Ser Val Gly Gly Asn Lys Met  
180 185 190

Gly Glu Gly Gly Phe Gly Val Val Tyr Lys Gly Tyr Val Asn Asn Thr  
 195 200 205  
 Thr Val Ala Val Lys Lys Leu Ala Ala Met Val Asp Ile Thr Thr Glu  
 210 215 220  
 Glu Leu Lys Gln Gln Phe Asp Gln Glu Ile Lys Val Met Ala Lys Cys  
 225 230 235 240  
 Gln His Glu Asn Leu Val Glu Leu Leu Gly Phe Ser Ser Asp Gly Asp  
 245 250 255  
 Asp Leu Cys Leu Val Tyr Val Tyr Met Pro Asn Gly Ser Leu Leu Asp  
 260 265 270  
 Arg Leu Ser Cys Leu Asp Gly Thr Pro Pro Leu Ser Trp His Met Arg  
 275 280 285  
 Cys Lys Ile Ala Gln Gly Ala Ala Asn Gly Ile Asn Phe Leu His Glu  
 290 295 300  
 Asn His His Ile His Arg Asp Ile Lys Ser Ala Asn Ile Leu Leu Asp  
 305 310 315 320  
 Glu Ala Phe Thr Ala Lys Ile Ser Asp Phe Gly Leu Ala Arg Ala Ser  
 325 330 335  
 Glu Lys Phe Ala Gln Thr Val Met Thr Ser Arg Ile Val Gly Thr Thr  
 340 345 350  
 Ala Tyr Met Ala Pro Glu Ala Leu Arg Gly Glu Ile Thr Pro Lys Ser  
 355 360 365  
 Asp Ile Tyr Ser Phe Gly Val Val Leu Leu Glu Ile Ile Thr Gly Leu  
 370 375 380  
 Pro Ala Val Asp Glu His Arg Glu Pro Gln Leu Leu Leu Asp Ile Lys  
 385 390 395 400  
 Glu Glu Ile Glu Asp Glu Glu Lys Thr Ile Glu Asp Tyr Ile Asp Lys  
 405 410 415  
 Lys Met Asn Asp Ala Asp Ser Thr Ser Val Glu Ala Met Tyr Ser Val  
 420 425 430  
 Ala Ser Gln Cys Leu His Glu Lys Lys Asn Lys Arg Pro Asp Ile Lys  
 435 440 445  
 Lys Val Gln Gln Leu Leu Gln Glu Met Thr Ala Ser  
 450 455 460

<210> 2

<211> 1383

<212> DNA

<213> Homo sapiens

<220>

<223> human IL-1 receptor-associated kinase 4 (IRAK-4)  
cDNA

<220>  
 <221> CDS  
 <222> (1) .. (1383)  
 <223> human IRAK-4

*B1 Cont'd*

<400> 2  
 atgaacaaac ccataacacc atcaacatat gtgcgctgcc tcaatgttgg actaattagg 60  
 aagctgtcag attttattga tcctcaagaa ggatggaaga agttagctgt agctattaaa 120  
 aaaccatctg gtgatgatag atacaatcag tttcacataa ggagatttga agcattactt 180  
 caaactggaa aaagtcccac ttctgaatta ctgtttgact ggggcaccac aaattgcaca 240  
 gctgggtgatc ttgtggatct tttgatccaa aatgaatttt ttgctcctgc gagtcttttg 300  
 ctcccagatg ctgttcccaa aactgctaata acactacctt cttaaagaagc tataacagtt 360  
 cagcaaaaac agatgccttt ctgtgacaaa gacaggacat tgatgacacc tgtgcagaat 420  
 cttgaacaaa gctatatgcc acctgactcc tcaagtccag aaaataaaaag tttagaagtt 480  
 agtgatacac gttttcacag tttttcattt tatgaattga agaattgtcac aaataacttt 540  
 gatgaacgac ccattttctgt tgggtggaat aaaatgggag agggaggatt tggagttgta 600  
 tataaaggct acgtaaataa cacaactgtg gcagtgaaga agcttgcagc aatggttgac 660  
 attactactg aagaactgaa acagcagttt gatcaagaaa taaaagtaat ggcaaagtgt 720  
 caacatgaaa acttagtaga actacttggg ttctcaagtg atggagatga cctctgctta 780  
 gtatatgttt acatgcctaa tgggttcattg cttagacagac tctcttgctt ggatggtact 840  
 ccaccacttt cttggcacat gagatgcaag attgtcagg gtgcagctaa tggcatcaat 900  
 tttctacatg aaaatcatca tattcataga gatattaaaa gtgcaaatat cttactggat 960  
 gaagctttta ctgctaaaat atctgacttt ggccttgcac gggcttctga gaagtttggc 1020  
 cagacagtca tgactagcag aattgtggga acaacagctt atatggcacc agaagctttg 1080  
 cgtggagaaa taacacccaa atctgatatt tacagctttg gtgtgggttt actagaaata 1140  
 ataactggac ttccagctgt ggatgaacac cgtgaacctc agttattgct agatattaaa 1200  
 gaagaaattg aagatgaaga aaagacaatt gaagattata ttgataaaaa gatgaatgat 1260  
 gctgattcca cttcagttga agctatgtac tctgttgcta gtcaatgtct gcatgaaaag 1320  
 aaaaataaga gaccagacat taagaaggtt caacagctgc tgcaagagat gacagcttct 1380  
 taa

<210> 3  
 <211> 459  
 <212> PRT  
 <213> Mus sp.

<400> 3  
 Met Asn Lys Pro Leu Thr Pro Ser Thr Tyr Ile Arg Asn Leu Asn Val  
 1 5 10 15  
 Gly Ile Leu Arg Lys Leu Ser Asp Phe Ile Asp Pro Gln Glu Gly Trp  
 20 25 30  
 Lys Lys Leu Ala Val Ala Ile Lys Lys Pro Ser Gly Asp Asp Arg Tyr  
 35 40 45  
 Asn Gln Phe His Ile Arg Arg Phe Glu Ala Leu Leu Gln Thr Gly Lys  
 50 55 60  
 Ser Pro Thr Cys Glu Leu Leu Phe Asp Trp Gly Thr Thr Asn Cys Thr  
 65 70 75 80  
 Val Gly Asp Leu Val Asp Leu Leu Val Gln Ile Glu Leu Phe Ala Pro  
 85 90 95  
 Ala Thr Leu Leu Leu Pro Asp Ala Val Pro Gln Thr Val Lys Ser Leu  
 100 105 110  
 Pro Pro Arg Glu Ala Ala Thr Val Ala Gln Thr His Gly Pro Cys Gln  
 115 120 125

Glu Lys Asp Arg Thr Ser Val Met Pro Met Pro Lys Leu Glu His Ser  
 130 135 140  
 Cys Glu Pro Pro Asp Ser Ser Ser Pro Asp Asn Arg Ser Val Glu Ser  
 145 150 155 160  
 Ser Asp Thr Arg Phe His Ser Phe Ser Phe His Glu Leu Lys Ser Ile  
 165 170 175  
 Thr Asn Asn Phe Asp Glu Gln Pro Ala Ser Ala Gly Gly Asn Arg Met  
 180 185 190  
 Gly Glu Gly Gly Phe Gly Val Val Tyr Lys Gly Cys Val Asn Asn Thr  
 195 200 205  
 Ile Val Ala Val Lys Lys Leu Gly Ala Met Val Glu Ile Ser Thr Glu  
 210 215 220  
 Glu Leu Lys Gln Gln Phe Asp Gln Glu Ile Lys Val Met Ala Thr Cys  
 225 230 235 240  
 Gln His Glu Asn Leu Val Glu Leu Leu Gly Phe Ser Ser Asp Ser Asp  
 245 250 255  
 Asn Leu Cys Leu Val Tyr Ala Tyr Met Pro Asn Gly Ser Leu Leu Asp  
 260 265 270  
 Arg Leu Ser Cys Leu Asp Gly Thr Pro Pro Leu Ser Trp His Thr Arg  
 275 280 285  
 Cys Lys Val Ala Gln Gly Thr Ala Asn Gly Ile Arg Phe Leu His Glu  
 290 295 300  
 Asn His His Ile His Arg Asp Ile Lys Ser Ala Asn Ile Leu Leu Asp  
 305 310 315 320  
 Lys Asp Phe Thr Ala Lys Ile Ser Asp Phe Gly Leu Ala Arg Ala Ser  
 325 330 335  
 Ala Arg Leu Ala Gln Thr Val Met Thr Ser Arg Ile Val Gly Thr Thr  
 340 345 350  
 Ala Tyr Met Ala Pro Glu Ala Leu Arg Gly Glu Ile Thr Pro Lys Ser  
 355 360 365  
 Asp Ile Tyr Ser Phe Gly Val Val Leu Leu Glu Leu Ile Thr Gly Leu  
 370 375 380  
 Ala Ala Val Asp Glu Asn Arg Glu Pro Gln Leu Leu Leu Asp Ile Lys  
 385 390 395 400  
 Glu Glu Ile Glu Asp Glu Glu Lys Thr Ile Glu Asp Tyr Thr Asp Glu  
 405 410 415  
 Lys Met Ser Asp Ala Asp Pro Ala Ser Val Glu Ala Met Tyr Ser Ala  
 420 425 430  
 Ala Ser Gln Cys Leu His Glu Lys Lys Asn Arg Arg Pro Asp Ile Ala  
 435 440 445

Lys Val Gln Gln Leu Leu Gln Glu Met Ser Ala  
450 455

<210> 4  
<211> 1542  
<212> DNA  
<213> Mus sp.

<220>  
<223> murine IL-1 receptor-associated kinase 4 (IRAK-4)  
cDNA

<220>  
<221> CDS  
<222> (163)..(1542)  
<223> murine IRAK-4

<400> 4  
gcggccgcgt cgacatgccc cggtgaccgc cagcatcccg atcgcaggca gtctgaagtc 60  
gcctgggtgg cctgcgtcct ccacccccga gtcctcgccg gacgtggcgg gacgccgatc 120  
gccttgtcca ggaagcgagg gacgtccgag aggaagtaga agatgaacaa gccgttgaca 180  
ccatcgacat acatacgcaa ccttaatgtg gggatcctta ggaagctgtc ggattttatt 240  
gatacctcaag aagggtggaa gaaattagca gtagctatca aaaagccgtc cggcgacgac 300  
agatacaatc agttccatat aaggagattc gaagccttac ttcagaccgg gaagagcccc 360  
acctgtgaac tgctgtttga ctggggcacc acgaactgca cagttggcga ccttgtggat 420  
ctactgggtcc agattgagct gtttgcccc gccactctcc tgctgccgga tgccgttccc 480  
caaaccgtca aaagcctgcc tcctagagaa gcggcaacag tggcacaac acacgggcct 540  
tgtcaggaaa aggacaggac atccgtaatg cctatgccga agctagaaca cagctgcgag 600  
ccaccggact cctcaagccc agacaacaga agtgtagagt ccagcgacac tcggttccac 660  
agcttctcgt tccatgaact gaagagcatc acaacaact tcgacgagca acccgctct 720  
gccgggtggca accggatggg agagggggga tttggagtgg tgtacaaggg ctgtgtgaac 780  
aacaccatcg tggcgggtgaa gaagctcgga gcgatgggtg aaatcagtac tgaagaacta 840  
aagcaacagt ttgatcaaga aattaaagta atggcaacgt gtcagcacga gaacctgggtg 900  
gagctgctcg gcttctccag cgacagcgac aacctgtgct tagtgtatgc ttacatgccc 960  
aacgggtcct tgctggacag actgtcctgc ctggatggta caccaccgct ttcttggcac 1020  
acaaggtgca aggttgctca ggggacagca aatggcatca ggtttctgca tgaaaatcat 1080  
cacattcata gagatattaa aagtgcaaat atcttactag acaaagactt tactgccaaa 1140  
atatctgact ttgggcttgc acgggcttcg gcaaggctag cgcagacggt catgaccagc 1200  
cgaatcgtgg gcacaacggc ttacatggca cccgaagctt tgcggggaga aataacaccc 1260  
aaatctgaca tctacagctt cggcgtgggt ctggtggagc tgataaccgg gctggcggct 1320  
gtggatgaaa accgtgaacc tcaactactg ctggatatta aagaagagat tgaagatgaa 1380  
gagaagacga ttgaagatta cacggatgag aagatgagcg atgcggaccc tgcttcggtg 1440  
gaagcaatgt actctgctgc tagccagtgt ctgcatgaga agaaaaacag acggccagac 1500  
attgcaaagg ttcaacagct gctacaagag atgtctgctt aa 1542

<210> 5  
<211> 34  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:sense primer  
for amplification of human IRAK-4

<400> 5  
atgaacaaac ccataacacc atcaacatat gtgc

34

<210> 6  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:antisense  
primer for amplification of human IRAK-4

<400> 6  
ttaagaagct gtcattctctt gcagc

25

<210> 7  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:epitope tag

<400> 7  
Asp Tyr Lys Asp Asp Asp Asp Lys  
1 5

---